We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications

By LabMedica International staff writers
Posted on 06 Sep 2024
Print article
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)
Image: The QIAstat-Dx IVD panel for neurodegenerative applications will be integrated with the QIAstat-Dx multiplex testing platform (Photo courtesy of QIAGEN)

QIAGEN N.V. (Venlo, the Netherlands) has entered into a collaboration with Eli Lilly and Company (Indianapolis, IN, USA) to support the development of a QIAstat-Dx in-vitro diagnostic (IVD) to detect APOE genotypes. The QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping and will detect all APOE genotypes (APOE2, APOE3, APOE4) which can play a role in the diagnosis of Alzheimer’s disease. People carrying the APOE4 genotype have a greater risk of developing Alzheimer's which is the most common cause of dementia and are likely to do so earlier in life in comparison to others. Individuals carrying two copies of this genotype (homozygous) are most likely to develop clinical symptoms of the disease.

The panel will be integrated with QIAGEN's multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for the system’s clinical application in neurodegenerative diseases. The QIAstat‑Dx system, designed for laboratory use, utilizes cost-efficient, single-use cartridges with built‑in sample processing and on-board reagents. Employing multiplex real-time PCR, it reliably detects genetic variants, with results in approximately one hour. With over 4,000 instruments placed worldwide, QIAstat‑Dx enjoys a strong footprint in infectious disease testing, which has now expanded into other disease and application areas.

“Our collaboration with Lilly to develop the QIAstat-Dx IVD panel underlines our commitment to advancing healthcare with a unique breadth of testing technologies and platforms, now also including multiplexing capabilities on QIAstat‑Dx,” said Jonathan Arnold, Vice President and Head of Translational Science and Precision Diagnostics at QIAGEN. “By providing precise APOE genotyping, we aim to better inform treatment considerations for Alzheimer’s patients, providing valuable insight in their diagnostic journey.”

“When offering a diagnostic test for clinical use, it is imperative that it be high-quality, accurate and accessible to patients,” added Anthony Sireci, M.D., MSc., Head of Diagnostics Development & Commercialization for Eli Lilly and Company. “We are working with QIAGEN to generate data for this APOE test because of their expertise in developing diagnostic assays and their global reach.”

Related Links:
QIAGEN N.V.
Eli Lilly and Company

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
New
Human Chorionic Gonadotropin Test
Humasis hCG Combo
New
Gastrointestinal Infection Test
RIDA QUICK Cryptosporidium/Giardia/Entamoeba Combi Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The study succeeded in early diagnosis of leptomeningeal disease in diffuse midline gliomas by liquid biopsy (Photo courtesy of Niigata University)

Liquid Biopsy Enables Early Diagnosis of Leptomeningeal Disease in Diffuse Midline Gliomas

Leptomeningeal disease (LMD) in diffuse midline gliomas (DMGs) can lead to debilitating symptoms such as intense pain, urinary incontinence, and tetraparesis, with limited treatment options available.... Read more

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: The diagnostic sensitivity of the interferon-γ release assay was higher in patients with COPD complicated with active pulmonary tuberculosis (Photo courtesy of Adobe Stock)

Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition and a major chronic lung disease that significantly impacts public health and work capacity. Long-term respiratory infections... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.